^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) (HER2 inhibitor, HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma
Excerpt:
A 71-year-old female presented in December 2017 after diagnosis of metastatic CCA….Guardant360 testing showed ERBB2 (HER2) amplification 3+...we began off label treatment with anti-HER2 pertuzumab/trastuzumab combination therapy….Immediate and rapid improvement of tumor markers was noted...Scans also showed excellent ongoing durable response...
DOI:
https://dx.doi.org/10.1038%2Fs41698-019-0091-4
